Activation of a temperature-sensitive form of mouse p53 in murine erythroleukaemia cells rapidly inhibits protein synthesis and causes early dephosphorylation and cleavage of protein synthesis initiation factor eIF4GI and the eIF4E-binding protein 4E-BP1. Dephosphorylated 4E-BP1 and the cleaved products of 4E-BP1 and eIF4GI associate with eIF4E under these conditions, concomitant with decreased interaction of full-length eIF4GI with eIF4E. These changes may play an important role in preventing formation of the eIF4F complex and thus the initiation of protein synthesis. As observed previously for eIF4GI, the cleavage of 4E-BP1 is insensitive to the general caspase inhibitor z-VAD.FMK, consistent with a caspase-independent mechanism of factor modification and regulation of protein synthesis. Comparison of the p53-induced patterns of eIF4GI and 4E-BP1 dephosphorylation and cleavage with those caused by the mTOR inhibitor rapamycin indicates that p53 activation and rapamycin have distinct but additive effects. Moreover, p53 activation inhibits rapamycin-insensitive protein kinase activity against 4E-BP1. P53 and rapamycin have additive effects on the inhibition of overall protein synthesis. These data suggest that the inhibition of protein synthesis by p53 is largely independent of the regulation of rapamycin-sensitive mTOR in the system under investigation.
Introduction
Activation of a temperature-sensitive form of the tumour suppressor protein p53 (Val 135 ) in murine erythroleukaemia (MEL) cells following a shift to the permissive temperature (321C) results in a block in cell cycle progression and subsequently causes apoptosis . Recent findings from our laboratory have shown that these effects are preceded by a progressive inhibition of protein synthesis. The p53-induced inhibition of protein synthesis commences at 2 h and progressively increases in magnitude whereas the cell cycle block and overt apoptosis only become apparent after 24 h of incubation at 321C. These data suggest that the downregulation of translation is not simply a consequence of the inhibition of cell proliferation or the loss of viability induced by p53. Contrary to other systems where the inhibition of protein synthesis induced by proapoptotic agents is caspase-dependent (Bushell et al., 1999 (Bushell et al., , 2000a (Bushell et al., , b, 2001 Jeffrey et al., 2002) , the regulation of translation in cells with active p53 appears to be independent of caspase activity .
Initiation of translation is a highly complex process involving several initiation factors (Sonenberg and Dever, 2003) . eIF4E is a very important factor whose function is to recognize the 7-methyl guanosine triphosphate (m 7 GTP) 'cap' at the 5 0 terminus of the mRNA, thereby allowing the latter to bind to the [40S subunit . eIF3 . eIF2] complex. For protein synthesis to take place, eIF4E must also interact with the large polypeptide initiation factor eIF4GI (or its homologue eIF4GII). The eIF4Gs play an important role in the initiation of translation by acting as scaffold molecules that interact with several other components of the ribosomal initiation complex (Hentze, 1997; Morley et al., 1997) . In vivo, eIF4GI or II exists in association with eIF4E and the ATP-dependent RNA helicase eIF4A in a complex referred to as eIF4F (Gingras et al., 1999b; Pre´voˆt et al., 2003) . The eIF4Gs also interact with the poly(A) binding protein (PABP) and it is believed that this facilitates the functional association of the 3 0 and 5 0 ends of the mRNA (Tarun Jr et al., 1997) . The association of eIF4GI with eIF4E enhances the binding of eIF4E to the cap (Haghighat and Sonenberg, 1997) .
The availability of eIF4E for mRNA binding is regulated by the eIF4E-binding proteins (4E-BPs), which sequester eIF4E and prevent the latter from interacting with the eIF4Gs (Marcotrigiano et al., 1999) . The 4E-BPs are targets for covalent modification by phosphorylation and this weakens their interaction with eIF4E, thereby allowing eIF4E to interact with eIF4GI/ II (Gingras et al., 1999b) . Phosphorylation of the 4E-BPs is achieved by activation of signalling pathways that regulate the protein kinase mammalian target of rapamycin (mTOR) (Gingras et al., 2001b) . The activity of this enzyme is under the control of P13-kinase/ Akt(PKB)-regulated and protein kinase C-regulated mechanisms (Gingras et al., 1998 (Gingras et al., , 1999a (Gingras et al., , b, 2001a Naveé t al., 1999; Schmelzle and Hall, 2000; Sekulic et al., 2000; Miron et al., 2003) . ) functioning together to promote subsequent phosphorylation of the more carboxy-terminal sites (Gingras et al., 1999a (Gingras et al., , 2001a .
We have reported previously that p53 activation causes caspase-independent cleavage of eIF4GI and dephosphorylation of 4E-BP1 (Horton et al., 2002; Constantinou et al., 2003) . In this study, we examine in more detail the sites of 4E-BP1 dephosphorylation and report the additional p53-induced, z-VAD.FMK-insensitive cleavage of 4E-BP1. We also show that the cleaved products of both eIF4GI and 4E-BP1 are capable of binding to eIF4E, thus potentially sequestering eIF4E from full-length eIF4GI. Furthermore, since 4E-BP1 phosphorylation is known to be under the control of mTOR, we have examined whether regulation of the latter enzyme by p53 is responsible for the changes in 4E-BP1 phosphorylation. Comparisons of the effects of treatment of cells with the mTOR inhibitor rapamycin with the effects of p53 activation suggest that a mechanism other than regulation of rapamycin-sensitive mTOR activity is responsible for the control of translation by p53.
Results

Dephosphorylation and modification of 4E-BP1 following p53 activation
Numerous previous studies have shown that, under conditions that block cell proliferation or induce apoptosis, the extent of phosphorylation of 4E-BP1 decreases (Lawrence Jr et al., 1997; Bushell et al., 2000b; Proud, 2000, 2001; Jeffrey et al., 2002) . Hypophosphorylated 4E-BP1 binds to eIF4E in competition with eIF4GI or II, thus decreasing the availability of the eIF4F complex for initiation of translation (Marcotrigiano et al., 1999; Karim et al., 2001) . We have reported previously that when cells expressing the Val 135 mutant form of p53 are incubated at 321C to activate the tumour suppressor, extensive 4E-BP1 dephosphorylation occurs. This is not the case when cells containing the Pro 190 mutant, which cannot be activated, are treated in the same manner (Horton et al., 2002; Constantinou et al., 2003) . The sites affected and the mechanisms underlying the p53-induced dephosphorylation, however, have not previously been established.
To address these questions Val 135 and Pro 190 cells were shifted from 38 to 321C. Figure 1a shows that p53 was activated in the Val  135 cells but not in the Pro  190 cells  under these conditions, as indicated by the induction of  the p53-target gene p21 waf1 only in the former. In order to determine which sites of phosphorylation in 4E-BP1 were affected by p53 activation, extracts from cells incubated at 321C for various lengths of time were immunoblotted with phosphospecific antibodies and with antibodies against total 4E-BP1. Electrophoresis of 4E-BP1 on high percentage (17.5%) polyacrylamide gels separates three different forms: g, b, and a. The g band represents the most highly phosphorylated form of the protein whereas the a band corresponds to the least phosphorylated form. Figure 1b ( dephosphorylation of 4E-BP1 may be attributable to the temperature shift per se, since there was some change in the Pro 190 cells also, but the effect was less marked and there was no significant decrease in the total amount of the protein in the latter cells (Figure 1b , compare lanes 1, 5 and 7). The p53-specific changes in the phosphorylation of 4E-BP1 were more obviously seen when sitespecific antibodies were employed. Figure 1b (Figure 1b, lane 8) .
Examination of the lower regions of the gels in these experiments also revealed the appearance of a more rapidly migrating form of 4E-BP1 at longer times after p53 activation (Figure 2a, right panel) . This effect, which was not observed in the Pro 190 cells incubated at 321C, is probably attributable to the proteolytic cleavage of 4E-BP1, as reported by Tee and Proud (2002) . We have shown previously that cleavage of initiation factor eIF4GI also takes place in this system within a few hours of p53 activation, giving rise to an approximately 80 kDa product, and that this occurs by an apparently caspase-independent mechanism . In view of this, we examined the sensitivity of the p53-induced cleavage of 4E-BP1 to inhibition of caspase activity. As can be seen in Figure 2a , the appearance of the smaller form of 4E-BP1 also appears to be independent of caspase activity since it was not prevented by the general caspase inhibitor z-VAD.FMK.
P53 activation causes increased binding of 4E-BP1 and the eIF4GI cleavage product to eIF4E Val 135 cells were incubated at 321C for the times indicated. Cytoplasmic extracts were prepared and initiation factor eIF4E and its associated proteins purified by m addition, the 80 kDa eIF4GI cleavage product (similar to the previously characterized protein MFAG; Bushell et al., 2000a) and a putative intermediate cleavage product also bound to eIF4E within 6 h of p53 activation ( Figure 2b , top and middle panels), consistent with previous findings (Bushell et al., 2000a) . We observed that the rapidly migrating 4E-BP1 cleavage product was also capable of binding eIF4E (Figure 2b , bottom panel), in agreement with the findings of Tee and Proud (2002) . These effects are quantified in Figure 2c . In the case of the control Pro 190 cells incubated at 321C, there was much less binding of 4E-BP1 to eIF4E (data not shown), in spite of the slight change in phosphorylation state of the former protein caused by the temperature shift (Figure 1b) . This indicates that the observed effects on eIF4F complex formation in the Val 135 cells were not due to the lower temperature per se. Our results suggest that the combined effects of the dephosphorylation of 4E-BP1 and the cleavages of both eIF4GI and 4E-BP1 brought about by p53 activation constitute a multifactorial mechanism leading to the sequestration of eIF4E away from full-length eIF4GI and causing the downregulation of cap-dependent translation.
P53 activation and rapamycin have distinct and additive effects on the state of phosphorylation and cleavage of 4E-BP1 and eIF4GI
The protein kinase mTOR regulates the phosphorylation of 4E-BP1 at several sites in a rapamycin-sensitive manner (Beretta et al., 1996) . Under certain conditions of physiological cell stress (e.g. serum starvation), mTOR activity is inhibited, resulting in 4E-BP1 dephosphorylation and a reduced rate of protein synthesis (Beretta et al., 1996; Gingras et al., 1998 Gingras et al., , 1999a Gingras et al., , b, 2001a Nave´et al., 1999; Schmelzle and Hall, 2000; Sekulic et al., 2000) . To determine if p53 activation and rapamycin act via the same or independent mechanisms to cause 4E-BP1 dephosphorylation, we compared the effects of these treatments on the sites and patterns of phosphorylation of 4E-BP1. Pro 190 and Val 135 cells were incubated at 38 or 321C in the presence or absence of rapamycin and the changes in the state of phosphorylation of distinct sites on 4E-BP1 were analysed. In confirmation of the results shown in Figure 1b All sites tested were observed to be dephosphorylated further than with either treatment alone and, in particular, very strong losses of signal were observed for both Ser 64 and Thr
45
. Together with the above results, these findings suggest that p53 activation and rapamycin treatment cause dephosphorylation of 4E-BP1 by distinct mechanisms.
To test further whether mTOR is regulated differently by p53 activation and rapamycin treatment, the same cell extracts were used to examine two sites of phosphorylation of mTOR itself. As shown in Figure 3b (lane 1 versus lane 3 and lane 2 versus lane 5), the shift in temperature from 38 to 321C itself caused some dephosphorylation at position Ser 2448 in both the Pro 190 and Val 135 cells (decreases of 42 and 52%, respectively) but the activation of p53 at the permissive temperature had relatively little effect. Ser 2448 is a site that is phosphorylated by Akt (protein kinase B) (Gingras et al., 1998; Nave´et al., 1999; Sekulic et al., 2000) and these findings therefore suggest that p53 does not significantly inhibit the Akt pathway that regulates mTOR. A similar conclusion was reached previously as a result of a direct Akt kinase assay in vitro (Horton et al., 2002 . The same cell extracts were also immunoblotted for atubulin as a control for equal protein loading. The positions of the a, b and g forms of 4E-BP1 are indicated. In (a) the relative band intensities of the combined a, b and g forms of 4E-BP1 were quantified by densitometry and are indicated below each set of blots (in arbitrary units). In (b) the relative band intensities of the total and phosphorylated forms of mTOR were quantified by densitometry and the ratios of the phosphorylated to total signals are indicated below the relevant blots. The data are representative of three similar experiments Regulation of eIF4GI and 4E-BP1 by p53 C Constantinou and MJ Clemens of phosphorylation of position Ser 2481 , which is an mTOR autophosphorylation site (Peterson et al., 2000) , was examined (Figure 3b) Figure 4a and c shows that the addition of rapamycin to Val 135 cells containing activated p53 not only caused further dephosphorylation of 4E-BP1 (as indicated by a shift from the b form to the a form) but also resulted in further cleavage of 4E-BP1 and the appearance of a second, even smaller product.
There was no cleavage of 4E-BP1 on addition of rapamycin to the Pro 190 cells. P53 activation and rapamycin increased the extent of cleavage of eIF4GI (Figure 4b and d) whereas rapamycin alone had no effect on eIF4GI cleavage. These results suggest that the rapamycin-mediated inhibition of mTOR is not sufficient to activate the protein cleavages but it can enhance the effect of p53 on these events. We also observed that the addition of rapamycin to cells with activated p53 caused further binding of the cleavage products of both eIF4GI and 4E-BP1 to eIF4E and under these conditions almost no full-length eIF4GI remained bound (data not shown). This suggests that the combined effects of p53 and rapamycin in causing accumulation of hypophosphorylated 4E-BP1, together with the appearance of cleaved forms of eIF4GI and 4E-BP1 that can also bind to eIF4E, result in a major loss of functional eIF4F complexes.
Since p53 activation causes dephosphorylation and cleavage of 4E-BP1, we extended the study to examine whether there was any dephosphorylation of eIF4GI under the same conditions. We performed immunoblot- 
P53 activation and rapamycin have additive effects on the inhibition of protein synthesis
Since p53 activation and rapamycin treatment had distinct and additive effects on initiation factor phosphorylation and cleavage, it was of interest to determine the consequences of these changes for overall protein synthesis. In spite of its effects on mTOR activity, when rapamycin was added to Val 135 cells growing at 381C there was very little inhibition of the overall rate of protein synthesis (Figure 6a) . A similarly small effect was observed when rapamycin was added to Pro 190 cells growing at 381C (data not shown). These findings are consistent with earlier observations in the literature (Marx and Marks, 1999; Martin et al., 2000) . When the Pro 190 cells were incubated at 321C in the presence of rapamycin, the drug again had very little effect on the rate of protein synthesis. However, its effect on the Val 135 cells at this temperature was additive with the much larger effect of p53 activation (Figure 6b ). This strongly suggests that p53 and rapamycin act on translation in MEL cells via distinct and additive mechanisms. Such a conclusion is entirely consistent with the enhancement by rapamycin of the dephosphorylation of 4E-BP1 (at most of the sites examined), of mTOR (at Ser 2481 ) and of eIF4GI (at Ser 1108 ), as well as of the cleavages of both 4E-BP1 and eIF4GI, in the cells with active p53.
Effects of p53 activation and rapamycin on phosphorylation of 4E-BP1 in vitro The evidence described above suggests that the phosphorylation of 4E-BP1 in cells with active p53 is regulated by a mechanism that is quite distinct from the mode of action of rapamycin. The observed decreases in phosphorylation of 4E-BP1 could be a and Val 135 cells were incubated at 381C or shifted to 321C for the times indicated, in the presence and absence of rapamycin, and protein synthesis was determined as described above. The data are the means7s.e.m. of three replicates for each condition Regulation of eIF4GI and 4E-BP1 by p53 C Constantinou and MJ Clemens consequence of an alternative mode of regulation of mTOR (Sarbassov et al., 2004) , or they could be due to inhibition of other protein kinases that utilize 4E-BP1 as a substrate. To investigate the effects of p53 activation on protein kinase activity, we have assayed changes in 4E-BP1 phosphorylation in vitro, using cell extracts prepared from Val 135 cells previously incubated at the nonpermissive and permissive temperatures in the absence or presence of rapamycin. Recombinant Histagged 4E-BP1 was employed as the substrate, in the presence of phosphatase inhibitors, and phosphorylation at different sites was assessed by immunoblotting with phospho-specific antibodies. Figure 7a shows Figure 7c ). The lack of inhibition of phosphorylation of 4E-BP1 at Thr 36/45 is consistent with similar observations in the literature (Gingras et al., 1999a (Gingras et al., , 2001b Mothe-Satney et al., 2000a) . On the other hand, the lack of inhibition of Ser 64 phosphorylation is surprising since rapamycin is known to affect this site and Ser 64 dephosphorylation of the endogenous 4E-BP1 did take place, confirming that rapamycin was functional in the cells (data not shown). Since the in vitro kinase assay was conducted in the presence of phosphatase inhibitors, it is possible that rapamycin regulates dephosphorylation of 4E-BP1 in the cell via activation of a phosphatase, as suggested by previous observations in the literature (Peterson et al., 1999; Gingras et al., 2004) . The most striking result in Figure 7b , however, is that when rapamycin was added to the cells containing active p53, a very marked inhibition of protein kinase activity towards all of the 4E-BP1 phosphorylation sites was observed (Figure 7b , lane 4 and Figure 7c ). This result suggests that at least two kinase activities are likely to be involved in phosphorylating the 4E-BP1 sites examined, viz. a rapamycin-sensitive activity that is not inhibited by p53 and a rapamycininsensitive activity that is inhibited by the tumour suppressor. It is only when both activities are blocked that a major decrease in 4E-BP1 phosphorylation becomes evident in vitro.
One candidate for a rapamycin-insensitive protein kinase that is known to be inhibited by p53 (Ababneh et al., 2001; Taylor and Stark, 2001) and that can also phosphorylate 4E-BP1 (Heesom et al., 2001 ) is the cyclin-regulated enzyme cdc2 (cdk1). As shown in Figure 8 , activation of p53 at the permissive temperature caused both a small decrease (no more than 20%) in the level of this enzyme and a more marked decrease in the extent of phosphorylation of cdc2. The latter was evident as both a preferential loss of the slowest migrating form of the protein (Figure 8a , top panel, lane 4) and reduced reactivity of immunoprecipitated cdc2 with a phosphospecific antibody against the Thr 161 activating site (Figure 8b , middle panel, lane 2) (Morgan, 1995) . In contrast, there was very little decrease in the phosphorylation of the protein at Tyr 15 , an inactivating site (Figure 8b , bottom panel, lane 2 Morla et al., 1989) . Densitometry of the immunoblots indicated that the ratio of Thr 161 to Tyr 15 signals decreased by about 50%. These data suggest that cdc2 kinase activity is decreased in the Val 135 cells at the temperature permissive for p53 activity. However, further studies are necessary to determine whether inhibition of the activity of cdc2 is sufficient to account for the effects of p53 on the state of 4E-BP1 phosphorylation and for the decrease in 4E-BP1 kinase activity that is additive with the decrease elicited by rapamycin. Regulation of eIF4GI and 4E-BP1 by p53 C Constantinou and MJ Clemens
Discussion
We have reported previously that activation of a temperature-sensitive form of the tumour suppressor protein p53 in MEL cells causes a rapid inhibition of protein synthesis and that this is accompanied by initiation factor cleavages and the dephosphorylation of 4E-BP1 (Horton et al., 2002; Constantinou et al., 2003) . In this paper, we have established more detailed kinetics for the latter effect and we have shown that there are also p53-induced specific modifications of 4E-BP1 that generate smaller fragments of this protein.
As a result of these changes, p53 activation leads to sequestration of eIF4E by hypophosphorylated and truncated forms of 4E-BP1. There is also increased binding of an eIF4GI cleavage product to eIF4E, concomitant with decreased binding of full-length eIF4GI. Some or all of these events are likely to have a significant inhibitory impact on cap-dependent initiation of protein synthesis. As shown previously for eIF4GI and eIF4B , the cleavage of 4E-BP1 is resistant to the general caspase inhibitor z-VAD.FMK, suggesting that either a z-VAD.FMK-insensitive caspase or another type of protease that is activated by p53 is responsible. However, failure of a wide range of inhibitors to block the cleavage in vivo and unpublished data) has so far precluded identification of the protease(s) responsible. There may be an important role for the eIF4GI and 4E-BP1 cleavage products in the regulation of the availability and/or activity of eIF4E. Both proteins are capable of binding to eIF4E, as shown by the m 7 GTP-Sepharose pull-down experiments. Our results are consistent with the observations of Bushell et al. (2000a) and Tee and Proud (2000) of binding of the cleavage products of eIF4GI and 4E-BP1 to eIF4E in cells treated with a protein synthesis inhibitor or a DNA-damaging agent, respectively. However, the cleavages of eIF4GI and 4E-BP1 described by these authors were prevented by z-VAD.FMK.
It is possible that the 80 kDa cleavage product of eIF4GI may still support some cap-dependent initiation when it is bound to eIF4E (Bushell et al., 2000a) . However, the sequestration of eIF4E by the hypophosphorylated and cleaved forms of 4E-BP1 would be expected to be inhibitory to initiation (Marcotrigiano et al., 1999) . Moreover, other studies have shown that cleaved 4E-BP1 cannot be rephosphorylated, thus limiting the reversibility of the inhibition (Tee and Proud, 2002) . It is possible that the cleaved form of 4E-BP1 binds to eIF4E more readily than the full-length protein since the former is more abundant, relative to full-length 4E-BP1, in the m 7 GTP-Sepharose-purified material than in the total cytoplasmic fraction (compare Figure 2b , lane 3 with Figure 2a , lane 5). Direct measurement of the relative affinities of the two forms of 4E-BP1 for eIF4E would be needed to confirm this.
Comparison of the changes in the state of phosphorylation of 4E-BP1 brought about by p53 activation with those that occur following treatment of cells with rapamycin revealed a number of differences. Moreover, the distinct effects of p53 and rapamycin on the distribution of 4E-BP1 between its a, b and g forms and on the state of phosphorylation of Ser 64 , Thr 69 and Thr 45 were additive when cells with active p53 were also treated with the mTOR inhibitor. These results are consistent with the finding that although rapamycin alone only inhibits overall protein synthesis to a small extent, even after 16 h, the inhibitory effect of the drug is additive with the much larger effect of p53 activation. We therefore suggest that p53 and rapamycin act via different pathways to cause the dephosphorylation of 4E-BP1, with distinct and additive consequences for the inhibition of protein synthesis. In addition, rapamycin enhances the extent of the specific cleavages of 4E-BP1 and eIF4GI induced by p53 and this too may contribute to the greater inhibition of protein synthesis. It is possible that the rapamycin-induced changes in the state of phosphorylation of 4E-BP1 (Figure 3a ) or eIF4GI ( Figure 5 ) could influence the susceptibility of these proteins to one or more proteases that are activated by p53.
The identities of the protein kinase(s) that may be regulated by p53 to cause the observed changes in 4E-BP1 phosphorylation in vivo remain to be established. The enzyme(s) affected appears to be rapamycininsensitive because: (i) in vitro, the phosphorylation of 4E-BP1 by cell extracts that still takes place after treatment of the cells with rapamycin is decreased following activation of p53; and (ii) in vivo, the p53-induced changes and the effects of rapamycin on 4E-BP1 phosphorylation are additive. Some reports have indicated that, under certain circumstances, mTOR can still be active in the presence of rapamycin (Edinger et al., 2003; Kudchodkar et al., 2004; Sarbassov et al., 2004) and it is possible that p53 inhibits such an activity of mTOR. However, there are also other candidates for rapamycin-insensitive protein kinase(s) that may phosphorylate Ser 64 and Thr 69 on 4E-BP1 and that could be inhibited by p53. Such enzymes previously implicated in 4E-BP1 phosphorylation include cdc2 (cdk1) (Heesom et al., 2001) and pim-2 (Fox et al., 2003) . Although there is no information concerning regulation of the latter, p53 has been shown to downregulate cdc2 expression at the level of transcription (Taylor et al., 1999) , and p53-activating stresses such as DNA damage regulate the phosphorylation of cdc2 (Poon et al., 1997) . It has also been reported that p53 can bind to cdc2 directly and inhibit the activity of this kinase (Ababneh et al., 2001) , and that overexpression of cdc2 suppresses p53-induced cell growth arrest (Park et al., 2000) . Heesom et al. (2001) showed that cdc2 is responsible for the phosphorylation of 4E-BP1 on Thr 70 (equivalent to Thr 69 in the murine protein) during mitosis. Thus, this enzyme is a strong candidate for a 4E-BP1 kinase that is regulated by p53. The mechanism of such a regulation in the MEL system remains to be established but it is likely to involve both changes in the level and activity of cdc2. The small decrease in the total cdc2 signal (Figure 8 ) may be a consequence of transcriptional downregulation of the enzyme (Taylor et al., 1999) . More significantly, Regulation of eIF4GI and 4E-BP1 by p53 C Constantinou and MJ Clemens the decrease in the ratio of the activating phosphorylation of cdc2 at Thr 161 to the inactivating phosphorylation at Tyr 15 will result in inhibition of cdc2 activity. This is likely to be more important for the regulation of the enzyme than inhibition by p21 (Poon et al., 1996) .
An additional possibility is that the extensive dephosphorylation of 4E-BP1 that is seen in cells with activated p53 is due to increased protein phosphatase activity. This is suggested by the rapid decrease in the extent of phosphorylation of Ser 64 in vivo (Figure 1b) at a time when there is only a modest inhibition of protein kinase activity directed towards this site in in vitro assays (Figure 7b) . Recently, several reports have shown that p53 is able to induce or activate novel protein phosphatases (Li et al., 2003; Ueda et al., 2003; Yin et al., 2003) but whether any of these act on 4E-BP1 remains to be established. It may be significant that the greatest p53-induced loss of phosphate from 4E-BP1 in vivo appears to involve Ser 64 , since this site can have a large influence on the binding of the protein to eIF4E (Mothe-Satney et al., 2000b; Karim et al., 2001) (although this conclusion has been challenged; Ferguson et al., 2003) . 4E-BP1 is phosphorylated in a hierarchical fashion, with Ser 64 being the last site to be modified when cells are stimulated by serum (Gingras et al., 1999a (Gingras et al., , 2001a . Our present data suggest that this site is also the first to be dephosphorylated, within 2 h of p53 activation (Figure 1b) . However, at later times Thr 69 and Thr 45 also become dephosphorylated. P53 activation not only causes dephosphorylation of 4E-BP1 but also of eIF4GI at Ser 1108 . This effect is visible as early as 3 h after cells are shifted to the p53-permissive temperature. As with 4E-BP1, the effect of p53 on phosphorylation of eIF4GI is additive with that of rapamycin, suggesting that distinct mechanisms may be responsible. Rapamycin, acting via inhibition of mTOR, has been shown to have only an indirect effect on the phosphorylation of Ser 1108 (Raught et al., 2000) , and the kinase that acts on this site has not been identified. It is not known whether this dephosphorylation has any effect on the activity of eIF4GI or on the susceptibility of this protein to cleavage or degradation. However, Ser 1108 lies close to a site in eIF4GI that is cleaved by caspase-3 in other systems (Bushell et al., 2000a) (previously designated Asp 1136 in the human sequence (Raught et al., 2000) but now renumbered Asp 1177 (Accession Number AAH66103)), and eIF4GI cleavage can also be observed within 3 h of shifting the Val 135 cells to 321C. In summary, our results suggest that dephosphorylation and specific cleavage of 4E-BP1 and/or eIF4GI constitute major components of the mechanism by which p53 activation causes inhibition of cap-dependent translation. It is now important to identify the protein kinase(s) and phosphatases involved in mediating the changes in the phosphorylation of these key factors. Moreover, it will be of interest to characterize the protease(s) responsible for the specific cleavages, particularly since these do not appear to correspond to any of the conventional caspases known to cleave eIF4GI and 4E-BP1 in other systems (Bushell et al., 1999; Tee and Proud, 2000) . It would also be interesting to know whether the state of phosphorylation of their substrates influences the abilities of these enzymes to cleave eIF4GI and 4E-BP1. Inhibition and/or modulation of the activities of the relevant enzymes should then make it possible to distinguish the individual contributions of the various modifications of eIF4GI and 4E-BP1 to the regulation of translation that follows the activation of p53.
Materials and methods
Materials
Antibody against total 4E-BP1 was purchased from Santa Cruz and phospho-specific 4E-BP1 antibodies were from Cell Signaling Technologies. Antibodies against eIF4E and eIF4GI were kindly provided by Dr Simon Morley (University of Sussex). Antibody against total cdc2(cdk1) was from Santa Cruz. Total mTOR and phospho-specific mTOR and cdc2 antibodies were from Cell Signaling Technologies and tubulinand His tag-specific antibodies were from Sigma. His-tagged recombinant 4E-BP1 was a gift from Dr Linda McKendrick (University of Sussex). Microcystin and sodium vanadate were from Alexis Biochemicals and Sigma, respectively.
Cell culture conditions
The Val 135 and Pro 190 MEL cell lines were obtained from Dr S Benchimol (Johnson et al., 1993) . They were grown in stationary suspension culture in DMEM medium supplemented with glutamine (300 mg/l) and fetal bovine serum (10% (v/v)) in a 5% CO 2 atmosphere at 381C. Under these conditions, both the cell lines had a doubling time of 12 h. Cultures were maintained at densities between 2 and 10 Â 10 5 cells per ml. Continued expression of p53 was assured by weekly selection of the cells in G418 (200 mg/ml). For activation of p53 in the Val 135 cells, the cultures were transferred to 321C for the times indicated. The Pro 190 cells were treated similarly. The latter cells served as a control for any effects of the temperature change per se since they contain a form of p53 that is inactive at both temperatures. The inhibitors z-VAD.FMK and rapamycin (Calbiochem) were added to the cells at the concentrations described in the Figure  legends .
Measurement of protein synthesis rates
Overall rates of protein synthesis were measured by pulse labelling intact cells for up to 1 h with 10 mCi/ml of [ 35 S] methionine (in the presence of the normal level of methionine in the cell culture medium). Aliquots of cells (0.3 ml) were then added to 5 ml of PBS and centrifuged at 1000 r.p.m. for 10 min. The supernatant was removed and the cells were precipitated with 10% (w/v) trichloroacetic acid. Precipitates were harvested on GF/C filters under suction and washed with 5% trichloroacetic acid and industrial methylated spirit. The acid-insoluble radioactiviy was determined by scintillation counting.
Preparation of cell extracts and analysis by immunoblotting
Cytoplasmic extracts were prepared for immunoblotting by washing 1 Â 10 7 cells in 1 ml of PBS and resuspending the pellet in 500 ml of cell lysis buffer (50 mM morpholinopropane sulphonic acid (MOPS), pH 7.5, 50 mM NaCl, 2 mM EDTA, Regulation of eIF4GI and 4E-BP1 by p53 C Constantinou and MJ Clemens 2 mM EGTA, 7 mM 2-mercaptoethanol and 0.2% NP40) containing a cocktail of the following phosphatase and proteinase inhibitors: 50 mM b-glycerophosphate, 2 mM sodium vanadate, 1 tablet of protease inhibitors (Complete Mini, EDTA-free protease inhibitor cocktail, Roche) per 10 ml of cell lysis buffer, 1 mM microcystin, and 1 mM phenylmethylsulphonylfluoride (PMSF). The lysed cells were then centrifuged, the supernatant (cytoplasmic extract) was removed and the protein content was analysed by the Bradford assay. The remaining pellet containing the nuclei was lysed directly into 2 Â SDS gel loading buffer. The cytoplasmic extracts were analysed by SDS gel electrophoresis with equal amounts of protein (10-20 mg) loaded in each lane of the gel. Nuclear extracts were analysed by loading equal volumes (equivalent to equal numbers of cells) in each lane of the gel. After transfer of the proteins to polyvinylidene difluoride membranes, the blots were blocked and incubated with the appropriate primary antibody. The blots were developed with horseradish peroxidase-linked secondary antibodies followed by enhanced chemiluminescence (Cell Signaling Technologies). The blots were scanned and the intensities of the bands quantified by densitometry using Scion Image software (Scioncorp, Frederick, MD, USA). GTP-Sepharose 4B resin (50% v/v) (Amersham Pharmacia) was washed in PBS and resuspended in cell lysis buffer. In all, 50ml of 50% resin was added to cell extracts containing 170 mg of protein and the mixtures were incubated for 25 min at 41C on an Eppendorf tube shaker. The beads and bound proteins were then isolated by centrifugation in a microcentrifuge at 41C and washed three times with 200 ml cell lysis buffer (without detergent). The pellets were resuspended in 40 ml 2 Â SDS sample buffer, boiled, centrifuged and the supernatants analyzed by SDS gel electrophoresis (20 ml sample per gel) and immunoblotting for eIF4E, eIF4GI and 4E-BP1.
Immunoprecipitation of cdc2 kinase
Whole-cell extracts were prepared by lysing cells in 50 mM Tris.HCl, pH 8.0, 0.5 M NaCl, 1% (v/v) NP40 containing a cocktail of protease and phosphatase inhibitors (1 tablet per 10 ml of Amersham protease inhibitors, 2 mM sodium vanadate, 1 mM microcystin, 7 mM 2-mercaptoethanol and 1 mM PMSF). Extracts (400 mg of protein) were added to 10 ml of cdc2 immunoprecipitating antibody (Santa Cruz) and allowed to incubate at 41C for 2 h. Then 20 ml of protein A-agarose (Sigma) was added. After incubation overnight at 41C, the mixture was briefly centrifuged and washed twice in the above lysis buffer. Proteins were eluted from the beads by the addition of 20 ml of 2 Â SDS sample buffer, heated for 5 min at 951C and then loaded on SDS polyacrylamide gels. The precipitated cdc2 was analysed by immunoblotting using two phosphospecific cdc2 antibodies (against Thr 161 and Tyr 15 ) (Cell Signaling Technologies), as well as the antibody used in the original immunoprecipitation.
In vitro phosphorylation of 4E-BP1
Val 135 cells were cultured at 381C or at 321C for 16 h, in the presence or absence of rapamycin (30 nM). Cells (4 Â 10 7 ) were lysed in 1 ml of a buffer containing 50 mM MOPS, pH 7.5, 25 mM KCl, 0.2% NP40 and the same phosphatase and proteinase inhibitors as above, and the protein concentration of each cell extract was determined by the Bradford method. For phosphorylation of 4E-BP1 in vitro cell extract (equivalent to 30 mg of protein) was incubated in a total volume of 25 ml with 5 mg of recombinant His-tagged 4E-BP1. The incubations contained 10 mM MgCl 2 , 25 mM MOPS, 2 mM dithiothreitol (DTT) and 1 mM ATP, with 0.5 mM microcystin added to inhibit protein phosphatase activity. Incubations were performed at 301C for 20-30 min (preliminary experiments had established that under these conditions the rate of reaction was linear and the extent of phosphorylation of 4E-BP1 was proportional to the amount of cell extract added). Reactions were stopped by the addition of an equal volume of 2 Â SDS gel sample buffer. The state of phosphorylation of 4E-BP1 was then determined by gel electrophoresis and immunoblotting with phospho-specific antibodies. In all cases, the amounts of recombinant 4E-BP1, total 4E-BP1 and cell extract protein in each incubation were checked by immunoblotting with antibodies against the His tag, total 4E-BP1 and a-tubulin, respectively. (Note that the amounts of the cell extracts used in these assays were sufficiently low that the endogenous 4E-BP1 made almost no contribution to the signals obtained by immunoblotting.) Abbreviations 4E-BPs, eIF4E-binding proteins; DTT, dithiothreitol; eIF, eukaryotic initiation factor; m 7 GTP, 7-methyl guanosine triphosphate; MEL, murine erythroleukaemia; MOPS, morpholinopropane sulphonic acid; mTOR, mammalian target of rapamycin; PMSF, phenylmethylsulphonylfluoride; z-VAD. FMK, benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone.
